KRYS - Krystal Biotech: Revisiting This Gene Therapy Pioneer Ahead Of Q2 Data
Shares of Krystal Biotech (KRYS) have risen by over 200% since my July 2018 article recommended readers accumulate shares based on optimism for the gene therapy pioneer's STAR-D platform and its potential to address multiple rare skin diseases. On the other hand, performance is only slightly in the green since my June update piece stated that thesis had strengthened considerably after promising phase 2 results for KB103 were reported in patients with dystrophic epidermolysis bullosa (DEB).
With the stock price bouncing up from April lows yet still below its 200- and 50-day moving averages ahead